Tocilizumab: Experience in a French rheumatological pediatric center;Traitement par tocilizumab: Expérience d'un centre de rhumatologie pédiatrique

Archives de Pediatrie

Volumn 21, Issue 12, 2014, Pages 1299-1304

  Le Stradic, C ^a   Galeotti, C ^a   Kone Paut I ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER ENZYME; TOCILIZUMAB; MONOCLONAL ANTIBODY;

ADOLESCENT; ANAPHYLAXIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; EXPERIENCE; FEMALE; FOLLOW UP; FRENCHMAN; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOCYTOPENIA; MACROPHAGE ACTIVATION SYNDROME; MALE; MULTICENTRIC CASTLEMAN DISEASE; NEUTROPENIA; PEDIATRIC HOSPITAL; RHEUMATOLOGY; SYSTEMIC JUVENILE RHEUMATOID ARTHRITIS; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ARTHRITIS, JUVENILE; EVALUATION STUDY; FRANCE; GIANT LYMPH NODE HYPERPLASIA; HOSPITAL; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; FEMALE; FRANCE; GIANT LYMPH NODE HYPERPLASIA; HOSPITALS, PEDIATRIC; HOSPITALS, SPECIAL; HUMANS; MALE; YOUNG ADULT;

EID: 84927597528     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/j.arcped.2014.08.018     Document Type: Article

References (15)

1. De Benedetti F. Targeting interleukin-6 in pediatric rheumatic diseases. Curr Opin Rheumatol 2009, 21:533-537.
2. De Benedetti F., Brunner H.I., Ruperto N., et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367:2385-2395.
3. Yokota S., Imagawa T., Mori M., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371:998-1006.
4. Yokota S., Imagawa T., Mori M., et al. Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open label extension study in Japan. Ann Rheum Dis 2013, 72:627-628.
5. Galeotti C., Boucheron A., Guillaume S., et al. Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6-receptor antibody. Mol Cancer Ther 2012, 11:1623-1626.
6. Smolen J.S., Beaulieu A., Rubbert-Roth A., et al. Effect of interleukin-6-receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997.
7. Nishimoto N., Kanakura Y., Aozasa K., et al. Humanized anti-interleukin-6-receptor antibody treatment of multicentric Castleman disease. Blood 2005, 106:2627-2632.
8. Woo P., Wilkinson N., Prieur A.M., et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6-receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005, 7:R1281-R1288.
9. Yokota S., Miyamae T., Imagawa T., et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6-receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005, 52:818-825.
10. Yokota S., Tanaka T., Kishimoto T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis 2012, 4:387-397.
11. Shimizu M., Nakagishi Y., Kasai K., et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine 2012, 58:287-294.
12. Pham T., Claudepierre P., Constantin A., et al. Tocilizumab: therapy and safety management. Joint Bone Spine 2010, 77(Suppl. 1):3-100.
13. Kessler E.A., Vora S.S., Verbsky J.W. Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome. Pediatr Rheumatol Online J 2012, 10:30.
14. Imagawa T., Yokota S., Mori M., et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol 2012, 22:109-115.
15. Alten R., Maleitzke T. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. Ann Med 2013, 45:357-363.